US Edition
Published • loading... • Updated
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
Summary by The AI Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
PRINCETON, N.J. and TOKYO, March 31, 2026 /PRNewswire/ — NJ Bio, Inc. (“NJ Bio”), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services (“Aji Bio‑Pharma”), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP, Aji Bio‑Pharma’s site‑specific conjugation platform for NJ Bio’s discovery‑stage …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
